Literature DB >> 6229264

Sensitization of normal and malignant tissue to cyclophosphamide by nitroimidazoles with different partition coefficients.

D G Hirst, J L Hazlehurst, J M Brown.   

Abstract

The ability of a range of 2-nitroimidazoles with similar electron affinities but widely differing partition coefficients (P) to enhance the cytotoxicity of cyclophosphamide (CY) in mouse tumour and normal tissues was investigated. In a preliminary study large single doses of benznidazole (BENZ), misonidazole (MISO), desmethylmisonidazole (DMM), and SR-2508 were found to give similar enhancement of the RIF-1 and SCC VII/St tumours. SR-2555 was less effective. A direct comparison was made between MISO and SR-2508 using prolonged, low-level drug exposures, achieved by multiple injections. The enhancement of CY cytotoxicity achieved in the two tumour systems (RIF-1 and SCC VII/St) was found to be similar for a given blood sensitizer concentration. In the normal tissue assays (white blood cell count, bone marrow CFU-S and testis spermatogonia) neither MISO nor SR-2508 produced significant enhancement of CY cytotoxicity, so that the therapeutic gains achieved at a given blood concentration of sensitizer were similar for SR-2508 and MISO. The main advantage of SR-2508, however, will probably lie in its lower toxicity, permitting higher blood levels to be achieved. However, the slope of the dose response curves are rather shallow so we would not predict a dramatically increased benefit.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6229264      PMCID: PMC1976681          DOI: 10.1038/bjc.1984.6

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  A direct measurement of the radiation sensitivity of normal mouse bone marrow cells.

Authors:  J E TILL; E A McCULLOCH
Journal:  Radiat Res       Date:  1961-02       Impact factor: 2.841

2.  Mechanism of sensitization of Chinese hamster ovary cells to melphalan by hypoxic treatment with misonidazole.

Authors:  Y C Taylor; J W Evans; J M Brown
Journal:  Cancer Res       Date:  1983-07       Impact factor: 12.701

3.  Nitroimidazole neurotoxicity: are mouse studies predictive?

Authors:  P J Conroy; T H McNeill; W Passalacqua; J Merritt; K R Reich; S Walker
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982 Mar-Apr       Impact factor: 7.038

4.  Structure-pharmacokinetic relationships for misonidazole analogues in mice.

Authors:  P Workman; J M Brown
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

5.  The therapeutic potential of misonidazole enhancement of alkylating agent cytotoxicity.

Authors:  D G Hirst; J M Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982 Mar-Apr       Impact factor: 7.038

6.  Enhancement by electron-affinic agents of the therapeutic effects of cytotoxic agents against the KHT tumor: structure-activity relationships.

Authors:  P Workman; P R Twentyman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982 Mar-Apr       Impact factor: 7.038

7.  Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.

Authors:  D W Siemann
Journal:  Br J Cancer       Date:  1982-02       Impact factor: 7.640

8.  Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide.

Authors:  M P Law; D G Hirst; J M Brown
Journal:  Br J Cancer       Date:  1981-08       Impact factor: 7.640

9.  Enhancement of the action of alkylating agents by single high, or chronic low doses of misonidazole.

Authors:  N J McNally; M Hinchliffe; J de Ronde
Journal:  Br J Cancer       Date:  1983-08       Impact factor: 7.640

10.  Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.

Authors:  D G Hirst; J M Brown; J L Hazlehurst
Journal:  Br J Cancer       Date:  1982-07       Impact factor: 7.640

View more
  1 in total

1.  Phase I/pharmacokinetic/biochemical study of the nitroimadazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide.

Authors:  P J O'Dwyer; F P LaCreta; J Walczak; T Cox; S Litwin; J P Hoffman; M Zimny; R L Comis
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.